HC-7366

The AVION study demonstrated that first-line avelumab plus axitinib is effective and safe for advanced renal cell carcinoma (RCC) in real-world settings.

The FDA granted priority review to fam-trastuzumab deruxtecan-nxki (T-DXd) for HER2-low/ultra-low breast cancer, potentially expanding treatment options for this patient subgroup.

The FDA has granted Fast Track designation to HC-7366 for treating adult patients with relapsed or refractory acute myeloid leukemia (AML).

HiberCell's HC-7366, a GCN2-activator, has been granted Fast Track designation by the FDA for treating relapsed or refractory acute myeloid leukemia (R/R AML).